Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

Background: Minimal residual disease (MRD) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (AML) patients. Approximately, 50% of AML patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizad Ghandforoush, Nasrin, Chahardouli, Bahram, Rostami, Shahrbano, Ghadimi, Habibeh, Ghasemi, Ali, Alimoghaddam, Kamran, Ghavamzadeh, Ardeshir, Nadali, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969559/
https://www.ncbi.nlm.nih.gov/pubmed/27489590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969559/
https://www.ncbi.nlm.nih.gov/pubmed/27489590

Ejemplares similares